<DOC>
	<DOCNO>NCT02314884</DOCNO>
	<brief_summary>A Phase I , Open-label , Dose-escalation Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Anti-tumor Activity Cafusertib Hydrochloride Patients With Advanced Solid Tumors</brief_summary>
	<brief_title>Phase I Trial Investigate Cafusertib Hydrochloride Monotherapy Chinese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description>To investigate safety , tolerability cafusertib Chinese patient Advanced Solid Tumors eligible conventional intensive treatment . The dose cafusertib escalate determine dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) cafusertib advance cancer patient . At time , pharmacokinetic characteristic preliminary efficacy cafusertib observe advanced cancer patient . To determine recommended dosage regimen phase II .</detailed_description>
	<criteria>Male female patient age 18 year 75 year time inform consent Eastern Cooperative Oncology Group performance status score 02 screen Life expectancy least 12 week At least one target tumor lesion irradiate accurately measure . Patients histologically cytologically confirm diagnosis advance solid tumor , fail conventional treatment , therapy efficacy exist . Signed informed consent consistent Chinese Good Clinical Practice . Male female patient childproducing potential must agree use appropriate contraceptive measure ( hormone barrier abstinence ) study 90 day last day treatment , serum pregnancy test must negative within 7 day prior initiation study treatment , infertile woman define hysterectomy , ovariotomy menopause least 12 month . Adequate bone marrow , renal hepatic function parameter : ANC 2000/mm3 , platelet count 100 000/mm3 , hemoglobin 90 g/L ; Total bilirubin less 1.5 x upper limit normal，ALT AST le 2.5 x upper limit normal，less 5.0 x upper limit normal case liver metastasis ; serum creatinine less 1.5 x upper limit normal , creatinine clearance rate 50 ml/min ( calculate accord CockcroftGault formula GFR estimate ) ; Relatively normal ECG ( electrocardiogram ) , QT intervals 450 m ( male ) , QT intervals 470 m ( female ) ; LVEF 50 % . Uncontrolled accumulation coelomic fluid . Any anticancer therapy , include chemotherapy , hormonal therapy , biologic therapy radiotherapy within 4 week prior initiation study treatment , receive nitrourea mitomycin chemotherapy within 6 week prior initiation study treatment . Side effects/toxicities surgery recover CTCAE grade 1 Patients ca n't interrupt use drug , may cause QT prolongation ( see annex 2 ) Patients meningioma current symptomatic brain metastasis Coexisting malignancy malignancy diagnose within last 5 year exception completely remove skin basal cell carcinoma cervical cancer situ Concurrent antitumor therapy Involved clinical trial le 4 week prior Day 1 Known hypersensitivity two substance trial drug excipients Patients serious infection Patients history immune deficiency , include positivity HIV antibody , acquire , congenital immunodeficiency disease , history organ transplantation Known positivity hepatitis B antigen hepatitis C antibody Patient serious disease , investigator 's opinion , bring patient great risk . Including limited following : unstable cardiac disease ( history myocardial infarction within 6 month prior Day 1 , New York Heart Association Class III great , poorly control atrial fibrillation hypertension ) , need longterm steroid immunosuppressive therapy disease , rheumatoid arthritis , multiple sclerosis systemic lupus erythematosus Pregnant ( positive pregnancy test ) lactate woman Active alcohol abuse heavy smoker A previous history neurological psychiatric disorder , include epilepsy dementia Subject think unfit study investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>